#BEGIN_DRUGCARD DB00980

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Rapid, total absorption is at least 84%.

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Rozerem

# CAS_Registry_Number:
196597-26-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C16H21NO2

# Chemical_IUPAC_Name:
N-{2-[(8S)-1H,2H,6H,7H,8H-indeno[5,4-b]furan-8-yl]ethyl}propanamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Hypnotics and Sedatives

# Drug_Interactions:
Atazanavir	Atazanavir increases levels/toxicity of ramelteon
Ciprofloxacin	Ciprofloxacin increases levels/toxicity of ramelteon
Enoxacin	Enoxacin increases levels/toxicity of ramelteon
Fluconazole	Fluconazole may increase the serum levels and toxcity of ramelteon.
Fluvoxamine	Fluvoxamine may increase the serum level and toxicity of ramelteon.
Ketoconazole	Ketoconazole may increase the serum levels and toxicity of ramelteon.
Mexiletine	Mexiletine increases levels/toxicity of ramelteon
Rifampin	Rifampin reduces the levels/effect of ramelteon
Tacrine	Tacrine increases levels/toxicity of ramelteon
Thiabendazole	Thiabendazole increases levels/toxicity of ramelteon
Triprolidine	The CNS depressants, Triprolidine and Ramelteon, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Zileuton	Zileuton increases levels/toxicity of ramelteon

# Drug_Reference:
16173650	Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar 1;28(3):303-7.
16432265	Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8.
17157111	Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55.
18729542	Simpson D, Curran MP: Ramelteon: a review of its use in insomnia. Drugs. 2008;68(13):1901-19.
19228178	Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51.
19568703	Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. Epub 2009 Jun 30.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.4

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Avoid alcohol.
Do not take with or immediately after a high-fat meal.

# GenBank_ID:
Not Available

# Generic_Name:
Ramelteon

# HET_ID:
Not Available

# Half_Life:
~1-2.6 hours

# InChI_Identifier:
InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1

# InChI_Key:
InChIKey=YLXDSYKOBKBWJQ-LBPRGKRZSA-N

# Indication:
For the treatment of insomnia characterized by difficulty with sleep onset.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
980

# Mechanism_Of_Action:
Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT<sub>1</sub> and MT<sub>2</sub> receptors, and lower selectivity for the MT<sub>3</sub> receptor.  Melatonin production is concurrent with nocturnal sleep, meaning that an increase in melatonin levels is related to the onset of self-reported sleepiness and an increase in sleep propensity. MT<sub>1</sub> receptors are believed to be responsible for regulation of sleepiness and facilitation of sleep onset, and MT<sub>2</sub> receptors are believed to mediate phase-shifting effects of melatonin on the circadian rhythm. While MT<sub>1</sub> and MT<sub>2</sub> receptors are associated with the sleep-wake cycle, MT<sub>3</sub> has a completely different profile, and therefore is not likely to be involved in the sleep-wake cycle. Remelteon has no appreciable affinity for the gamma-aminobutyric acid (GABA) receptor complex or receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
259.3434

# Molecular_Weight_Mono:
259.157228921

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164744896

# Pharmacology:
Ramelteon is the first selective melatonin agonist. It works by mimicking melatonin (MT), a naturally occuring hormone that is produced during the sleep period and thought to be responsible for the regulation of circadian rhythm underlying the normal sleep-wake cycle. Ramelteon has a high affinity for the MT<sub>1</sub> and MT<sub>2</sub> receptors. The MT<sub>1</sub> and MT<sub>2</sub> receptors are located in the brain's suprachiasmatic nuclei (SCN),which is known as the body's "master clock" because it regulates the 24-hour sleep-wake cycle. Ramelteon has an active metabolite that is less potent but circulates in higher concentrations than the parent compound. The metabolite also has weak affinity for the 5HT2b receptor.

# Predicted_LogP_Hydrophobicity:
3.03

# Predicted_LogS:
-4.2

# Predicted_Water_Solubility:
1.64e-02 g/l

# Primary_Accession_No:
DB00980

# Protein_Binding:
~82% (in human serum)

# PubChem_Compound_ID:
208902

# PubChem_Substance_ID:
46505923

# RxList_Link:
http://www.rxlist.com/cgi/generic4/rozerem.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01213

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
TAK-375

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:48 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ramelteon

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_1_ID:
4200

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05177

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_3_ID:
6016

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P33261

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
15695169	Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005 Feb;48(2):301-10.
15869323	Ramelteon: TAK 375. Drugs R D. 2005;6(3):186-8.
16173650	Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar 1;28(3):303-7.
16432265	Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8.
16730121	Miyamoto M: Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci Lett. 2006 Jul 24;402(3):201-4. Epub 2006 May 24.
17015817	Johnson MW, Suess PE, Griffiths RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57.
17157111	Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55.
17389558	Greenblatt DJ, Harmatz JS, Karim A: Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007 Apr;47(4):485-96.
17803013	Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504.
19228178	Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51.
19568703	Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. Epub 2009 Jun 30.
19768947	Miyamoto M: [A novel therapeutic drug: ramelteon] Nippon Rinsho. 2009 Aug;67(8):1595-600.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
MTNR1A

# Drug_Target_1_GenBank_ID_Gene:
U14108

# Drug_Target_1_GenBank_ID_Protein:
602130

# Drug_Target_1_GeneCard_ID:
MTNR1A

# Drug_Target_1_Gene_Name:
MTNR1A

# Drug_Target_1_Gene_Sequence:
>1053 bp
ATGCAGGGCAACGGCAGCGCGCTGCCCAACGCCTCCCAGCCCGTGCTCCGCGGGGACGGC
GCGCGGCCCTCGTGGCTGGCGTCCGCCCTAGCCTGCGTCCTCATCTTCACCATCGTGGTG
GACATCCTGGGCAACCTCCTGGTCATCCTGTCGGTGTATCGGAACAAGAAGCTCAGGAAC
GCAGGAAACATCTTTGTGGTGAGCTTAGCGGTGGCAGACCTGGTGGTGGCCATTTATCCG
TACCCGTTGGTGCTGATGTCGATATTTAACAACGGGTGGAACCTGGGCTATCTGCACTGC
CAAGTCAGTGGGTTCCTGATGGGCCTGAGCGTCATCGGCTCCATATTCAACATCACCGGC
ATCGCCATCAACCGCTACTGCTACATCTGCCACAGTCTCAAGTACGACAAACTGTACAGC
AGCAAGAACTCCCTCTGCTACGTGCTCCTCATATGGCTCCTGACGCTGGCGGCCGTCCTG
CCCAACCTCCGTGCAGGGACTCTCCAGTACGACCCGAGGATCTACTCGTGCACCTTCGCC
CAGTCCGTCAGCTCCGCCTACACCATCGCCGTGGTGGTTTTCCACTTCCTCGTCCCCATG
ATCATAGTCATCTTCTGTTACCTGAGAATATGGATCCTGGTTCTCCAGGTCAGACAGAGG
GTGAAACCTGACCGCAAACCCAAACTGAAACCACAGGACTTCAGGAATTTTGTCACCATG
TTTGTGGTTTTTGTCCTCTTTGCCATTTGCTGGGCTCCTCTGAACTTCATTGGCCTGGCC
GTGGCCTCTGACCCCGCCAGCATGGTGCCTAGGATCCCAGAGTGGCTGTTTGTGGCCAGT
TACTACATGGCGTATTTCAACAGCTGCCTCAATGCCATTATATACGGGCTACTGAACCAA
AATTTCAGGAAGGAATACAGGAGAATTATAGTCTCGCTCTGTACAGCCAGGGTGTTCTTT
GTGGACAGCTCTAACGACGTGGCCGATAGGGTTAAATGGAAACCGTCTCCACTGATGACC
AACAATAATGTAGTAAAGGTGGACTCCGTTTAA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
10471411	Ebisawa T, Kajimura N, Uchiyama M, Katoh M, Sekimoto M, Watanabe T, Ozeki Y, Ikeda M, Jodoi T, Sugishita M, Iwase T, Kamei Y, Kim K, Shibui K, Kudo Y, Yamada N, Toyoshima R, Okawa M, Takahashi K, Yamauchi T: Alleic variants of human melatonin 1a receptor: function and prevalence in subjects with circadian rhythm sleep disorders. Biochem Biophys Res Commun. 1999 Sep 7;262(3):832-7.
7946354	Reppert SM, Weaver DR, Ebisawa T: Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994 Nov;13(5):1177-85.

# Drug_Target_1_HGNC_ID:
HGNC:7463

# Drug_Target_1_HPRD_ID:
02812

# Drug_Target_1_ID:
571

# Drug_Target_1_Locus:
4q35.1

# Drug_Target_1_Molecular_Weight:
39375

# Drug_Target_1_Name:
Melatonin receptor type 1A

# Drug_Target_1_Number_of_Residues:
350

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Melatonin receptor type 1A
MQGNGSALPNASQPVLRGDGARPSWLASALACVLIFTIVVDILGNLLVILSVYRNKKLRN
AGNIFVVSLAVADLVVAIYPYPLVLMSIFNNGWNLGYLHCQVSGFLMGLSVIGSIFNITG
IAINRYCYICHSLKYDKLYSSKNSLCYVLLIWLLTLAAVLPNLRAGTLQYDPRIYSCTFA
QSVSSAYTIAVVVFHFLVPMIIVIFCYLRIWILVLQVRQRVKPDRKPKLKPQDFRNFVTM
FVVFVLFAICWAPLNFIGLAVASDPASMVPRIPEWLFVASYYMAYFNSCLNAIIYGLLNQ
NFRKEYRRIIVSLCTARVFFVDSSNDVADRVKWKPSPLMTNNNVVKVDSV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity

# Drug_Target_1_SwissProt_ID:
P48039

# Drug_Target_1_SwissProt_Name:
MTR1A_HUMAN

# Drug_Target_1_Synonyms:
Mel-1A-R
Mel1a melatonin receptor

# Drug_Target_1_Theoretical_pI:
9.75

# Drug_Target_1_Transmembrane_Regions:
30-50
64-84
103-123
143-163
188-208
241-261
275-295

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
15695169	Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005 Feb;48(2):301-10.
15869323	Ramelteon: TAK 375. Drugs R D. 2005;6(3):186-8.
16173650	Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar 1;28(3):303-7.
16432265	Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8.
16730121	Miyamoto M: Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci Lett. 2006 Jul 24;402(3):201-4. Epub 2006 May 24.
17015817	Johnson MW, Suess PE, Griffiths RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57.
17157111	Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55.
17389558	Greenblatt DJ, Harmatz JS, Karim A: Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007 Apr;47(4):485-96.
17803013	Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504.
19228178	Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51.
19568703	Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. Epub 2009 Jun 30.
19768947	Miyamoto M: [A novel therapeutic drug: ramelteon] Nippon Rinsho. 2009 Aug;67(8):1595-600.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
MTNR1B

# Drug_Target_2_GenBank_ID_Gene:
U25341

# Drug_Target_2_GenBank_ID_Protein:
971194

# Drug_Target_2_GeneCard_ID:
MTNR1B

# Drug_Target_2_Gene_Name:
MTNR1B

# Drug_Target_2_Gene_Sequence:
>1089 bp
ATGTCAGAGAACGGCTCCTTCGCCAACTGCTGCGAGGCGGGCGGGTGGGCAGTGCGCCCG
GGCTGGTCGGGGGCTGGCAGCGCGCGGCCCTCCAGGACCCCTCGACCTCCCTGGGTGGCT
CCAGCGCTGTCCGCGGTGCTCATCGTCACCACCGCCGTGGACGTCGTGGGCAACCTCCTG
GTGATCCTCTCCGTGCTCAGGAACCGCAAGCTCCGGAACGCAGGTAATTTGTTCTTGGTG
AGTCTGGCATTGGCTGACCTGGTGGTGGCCTTCTACCCCTACCCGCTAATCCTCGTGGCC
ATCTTCTATGACGGCTGGGCCCTGGGGGAGGAGCACTGCAAGGCCAGCGCCTTTGTGATG
GGCCTGAGCGTCATCGGCTCTGTCTTCAATATCACTGCCATCGCCATTAACCGCTACTGC
TACATCTGCCACAGCATGGCCTACCACCGAATCTACCGGCGCTGGCACACCCCTCTGCAC
ATCTGCCTCATCTGGCTCCTCACCGTGGTGGCCTTGCTGCCCAACTTCTTTGTGGGGTCC
CTGGAGTACGACCCACGCATCTATTCCTGCACCTTCATCCAGACCGCCAGCACCCAGTAC
ACGGCGGCAGTGGTGGTCATCCACTTCCTCCTCCCTATCGCTGTCGTGTCCTTCTGCTAC
CTGCGCATCTGGGTGCTGGTGCTTCAGGCCCGCAGGAAAGCCAAGCCAGAGAGCAGGCTG
TGCCTGAAGCCCAGCGACTTGCGGAGCTTTCTAACCATGTTTGTGGTGTTTGTGATCTTT
GCCATCTGCTGGGCTCCACTTAACTGCATCGGCCTCGCTGTGGCCATCAACCCCCAAGAA
ATGGCTCCCCAGATCCCTGAGGGGCTATTTGTCACTAGCTACTTACTGGCTTATTTCAAC
AGCTGCCTGAATGCCATTGTCTATGGGCTCTTGAACCAAAACTTCCGCAGGGAATACAAG
AGGATCCTCTTGGCCCTTTGGAACCCACGGCACTGCATTCAAGATGCTTCCAAGGGCAGC
CACGCGGAGGGGCTGCAGAGCCCAGCTCCACCCATCATTGGTGTGCAGCACCAGGCAGAT
GCTCTCTAG

# Drug_Target_2_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_2_General_References:
10696804	Ebisawa T, Uchiyama M, Kajimura N, Kamei Y, Shibui K, Kim K, Kudo Y, Iwase T, Sugishita M, Jodoi T, Ikeda M, Ozeki Y, Watanabe T, Sekimoto M, Katoh M, Yamada N, Toyoshima R, Okawa M, Takahashi K, Yamauchi T: Genetic polymorphisms of human melatonin 1b receptor gene in circadian rhythm sleep disorders and controls. Neurosci Lett. 2000 Feb 11;280(1):29-32.
7568007	Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF: Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8734-8.

# Drug_Target_2_HGNC_ID:
HGNC:7464

# Drug_Target_2_HPRD_ID:
02882

# Drug_Target_2_ID:
362

# Drug_Target_2_Locus:
11q21-q22

# Drug_Target_2_Molecular_Weight:
40189

# Drug_Target_2_Name:
Melatonin receptor type 1B

# Drug_Target_2_Number_of_Residues:
362

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Melatonin receptor type 1B
MSENGSFANCCEAGGWAVRPGWSGAGSARPSRTPRPPWVAPALSAVLIVTTAVDVVGNLL
VILSVLRNRKLRNAGNLFLVSLALADLVVAFYPYPLILVAIFYDGWALGEEHCKASAFVM
GLSVIGSVFNITAIAINRYCYICHSMAYHRIYRRWHTPLHICLIWLLTVVALLPNFFVGS
LEYDPRIYSCTFIQTASTQYTAAVVVIHFLLPIAVVSFCYLRIWVLVLQARRKAKPESRL
CLKPSDLRSFLTMFVVFVIFAICWAPLNCIGLAVAINPQEMAPQIPEGLFVTSYLLAYFN
SCLNAIVYGLLNQNFRREYKRILLALWNPRHCIQDASKGSHAEGLQSPAPPIIGVQHQAD
AL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity

# Drug_Target_2_SwissProt_ID:
P49286

# Drug_Target_2_SwissProt_Name:
MTR1B_HUMAN

# Drug_Target_2_Synonyms:
Mel-1B-R
Mel1b melatonin receptor

# Drug_Target_2_Theoretical_pI:
8.91

# Drug_Target_2_Transmembrane_Regions:
43-63
77-97
116-136
156-176
201-221
254-274
288-308

#END_DRUGCARD DB00980
